20vPnC

Pipeline

Status by Indication[2][1]

Competition

Competitive Landscape

2 competitors in Pneumococcal Disease

#DrugCompanyPhaseTrials

1

Pneumococcal Vaccine

GSK

Phase 3

12

20vPnC

Pfizer

Phase 3

3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Clinical

Trials by Indication[1]

Pneumococcal Disease3 trials

A PHASE 1, OPEN-LABEL STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF A 20-VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY CHINESE ADULTS, CHILDREN, AND INFANTS

Active, not recruiting·Pfizer·Phase 1·NCT07023081·200 enrolled

A PHASE 3, RANDOMIZED, DOUBLE-BLIND TRIAL TO EVALUATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF 3 LOTS OF A MULTIVALENT PNEUMOCOCCAL CONJUGATE VACCINE IN ADULTS

Recruiting·Pfizer·Phase 3·NCT07794748·4,670 enrolled

A PHASE 3, RANDOMIZED, DOUBLE-BLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF 20-VALENT PNEUMOCOCCAL CONJUGATE VACCINE (20VPNC) IN HEALTHY CHINESE INFANTS

Recruiting·Pfizer·Phase 3·NCT07754539·1,250 enrolled

Details

Drug Info

Related News